Latest From Agenus Inc.
Finance Watch: Panic Over FDA Commissioner's Resignation Was Short-Lived, Though IPOs Still Languish
Public Company Edition: Biotech stocks sank when US FDA Commissioner Scott Gottlieb announced his departure, but have nearly recovered to pre-resignation levels, except for newly public firms. Also, Biohaven's raises cash for PRV purchase and Endo issues $1.5bn in new debt.
Public Company Edition: Four more IPOs in the US bring the year's total to seven – all in February. Also, Agenus launched its digital security offering, MacroGenics leads recent follow-on offerings and four companies reveal new job cuts.
Investors in a February Biotech Electronic Security Token (BEST) offering will be able to put their money behind a single Agenus asset – the PD-1 inhibitor AGEN2034. Also, financial and strategic updates from Gossamer, Aduro, Novo's REPAIR Impact Fund and more.
Bluebird licenses Inhibrx’s single-domain antibody technology for use in constructs for CAR-T therapy generation. Jazz pays $56m up front under an engineered exosome collaboration with Codiak.
- Large Molecule
- Therapeutic Areas
- Infectious & Viral Diseases
- Antigenics Inc.
- North America
- Parent & Subsidiaries
- Agenus Inc.
- Senior Management
Garo H Armen, PhD, Chmn. & CEO
Christian Cortis, Chief Strategy Officer & Head, Fin.
Alex Duncan, PhD, CTO
Julie DeSander, VP, Bus. Dev. & Alliance Mngmt.
Jennifer Buell, PhD, COO
- Contact Info
Phone: (781) 674-4400
3 Forbes Rd.
Lexington, MA 02421-7305
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.